HomeCirculation ResearchVol. 129, No. 10In This Issue Free AccessIn BriefPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessIn BriefPDF/EPUBIn This Issue Ruth Williams Ruth WilliamsRuth Williams Search for more papers by this author Originally published28 Oct 2021https://doi.org/10.1161/RES.0000000000000516Circulation Research. 2021;129:891is related toMacrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NGChaperone-Mediated Autophagy of eNOS in Myocardial Ischemia-Reperfusion InjuryEfficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG (p 895)Ma et al perform base editing in mouse embryos to prevent hypertrophic cardiomyopathy.Download figureDownload PowerPointInherited hypertrophic cardiomyopathy (HCM), characterized by thickening and dysfunction of the heart muscle, is the most common genetic heart disorder. Mutations causing HCM often affect a single gene, such as the myosin heavy chain (MHC) gene, and as such have the potential to be corrected by gene editing style approaches. Not all editing techniques are the same, however, with some potentially introducing unwanted insertions or deletions of nucleotides (indels) at the target site. Ma and colleagues wondered whether base editing—in which a single nucleotide basepair is corrected and which typically doesn’t lead to indels—might be a safer approach. The team created a base-editor system to convert an HCM-causing A-T basepair into the wildtype G-C at a single point in the mouse Mhc6 gene. Transfection of the base-editing system into single-cell zygotes resulted in a correction rate of approximately 60-70 percent and, after transfer of the corrected embryos into surrogate females, prevented HCM in the postnatal animals. The team also performed base editing on mouse embryos in utero, achieving a 25 percent gene correction rate. The approach did not cause detectable indels or off-target editing, the team showed, suggesting it might have potential for development as a clinical tool.Macrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4 (p 909)Heart-repair via MST1 inhibition may be hindered by inflammatory effects, say Liu et al, who suggest a pharmacological work-around.Download figureDownload PowerPointAfter a myocardial infarction, the injured heart muscle is largely unable to regenerate and instead forms a dysfunctional scar that can ultimately lead to heart failure. Cardiomyocyte-specific inhibition of the kinase MST1—shown to boost repair and regeneration in other organs—can prevent infarction-induced death of these cells and preserve heart function, suggesting it may have clinical utility. However, MST1 also has anti-inflammatory properties in macrophages. Its inhibition in those cells may thus delay inflammation resolution after infarction and impair proper healing. Liu and colleagues have now examined mice lacking MST1 in macrophages and found that, sure enough, after myocardial infarction the inflammatory mediator leukotriene B4 was upregulated in macrophages and the animals’ heart function was reduced compared to that of wildtype controls. Importantly, blocking the action of leukotriene B4 in mice reduced infarction injuries in the hearts of MST1-lacking animals and enhanced repair in the injured hearts of wildtype animals given an MST1 inhibitor. The results suggest that, if MST1 inhibition is used as a future post-infarction regenerative therapy, then leukotriene B4 blockade may prevent its inflammatory side-effects.Chaperone-Mediated Autophagy of eNOS in Myocardial Ischemia-Reperfusion Injury (p 930)Maintaining nitric oxide synthase function after reperfusion injury protects the heart from damage, say Subramani et al.Download figureDownload PowerPointRestoring blood flow to ischemic heart muscle after a myocardial infarction is critical for salvaging muscle function, but can itself cause damage—so-called reperfusion injury. The generation of reactive oxygen species (ROS) and loss of nitric oxide (NO) both contribute to such injury, and the situation is exacerbated by the NO-producing enzyme, endothelial NO synthase (eNOS), producing damaging superoxide anions instead of NO. This switch in eNOS function is caused by glutathionylation of the enzyme (SG-eNOS), but how long the malfunction lasts and how it is rectified is unclear. Subramani and colleagues show that in human endothelial cells exposed to several hours of hypoxia followed by reoxygenation, the level of SG-eNOS steadily increases until, at 16 hours, it decreases sharply. By blocking several different cellular degradation pathways, the team discovered that this decrease in SG-eNOS was due to chaperone-mediated autophagy, with chaperone protein HSC70 being responsible for SG-eNOS destruction. Importantly, the team went on to show that pharmacological deglutathionylation of eNOS in mice promoted NO production and reduced reperfusion injury, suggesting this approach may be of clinical benefit after a myocardial infarction. Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesMacrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4Mingming Liu, et al. Circulation Research. 2021;129:909-926Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NGShuhong Ma, et al. Circulation Research. 2021;129:895-908Chaperone-Mediated Autophagy of eNOS in Myocardial Ischemia-Reperfusion InjuryJaganathan Subramani, et al. Circulation Research. 2021;129:930-945 October 29, 2021Vol 129, Issue 10Article InformationMetrics © 2021 American Heart Association, Inc.https://doi.org/10.1161/RES.0000000000000516 Originally publishedOctober 28, 2021 PDF download Advertisement
Read full abstract